353 related articles for article (PubMed ID: 9469685)
1. Update: clinically significant cytochrome P-450 drug interactions.
Michalets EL
Pharmacotherapy; 1998; 18(1):84-112. PubMed ID: 9469685
[TBL] [Abstract][Full Text] [Related]
2. Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes.
Lim HK; Duczak N; Brougham L; Elliot M; Patel K; Chan K
Drug Metab Dispos; 2005 Aug; 33(8):1211-9. PubMed ID: 15860655
[TBL] [Abstract][Full Text] [Related]
3. Optimizing higher throughput methods to assess drug-drug interactions for CYP1A2, CYP2C9, CYP2C19, CYP2D6, rCYP2D6, and CYP3A4 in vitro using a single point IC(50).
Gao F; Johnson DL; Ekins S; Janiszewski J; Kelly KG; Meyer RD; West M
J Biomol Screen; 2002 Aug; 7(4):373-82. PubMed ID: 12230892
[TBL] [Abstract][Full Text] [Related]
4. In vitro study on the involvement of CYP1A2, CYP2D6 and CYP3A4 in the metabolism of haloperidol and reduced haloperidol.
Pan L; Belpaire FM
Eur J Clin Pharmacol; 1999 Oct; 55(8):599-604. PubMed ID: 10541779
[TBL] [Abstract][Full Text] [Related]
5. Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib.
Uttamsingh V; Lu C; Miwa G; Gan LS
Drug Metab Dispos; 2005 Nov; 33(11):1723-8. PubMed ID: 16103134
[TBL] [Abstract][Full Text] [Related]
6. In vitro metabolism of the calmodulin antagonist DY-9760e (3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate) by human liver microsomes: involvement of cytochromes p450 in atypical kinetics and potential drug interactions.
Tachibana S; Fujimaki Y; Yokoyama H; Okazaki O; Sudo K
Drug Metab Dispos; 2005 Nov; 33(11):1628-36. PubMed ID: 16049129
[TBL] [Abstract][Full Text] [Related]
7. Competition between cytochrome P-450 isozymes for NADPH-cytochrome P-450 oxidoreductase affects drug metabolism.
Li DN; Pritchard MP; Hanlon SP; Burchell B; Wolf CR; Friedberg T
J Pharmacol Exp Ther; 1999 May; 289(2):661-7. PubMed ID: 10215637
[TBL] [Abstract][Full Text] [Related]
8. Effect of chronic disulfiram administration on the activities of CYP1A2, CYP2C19, CYP2D6, CYP2E1, and N-acetyltransferase in healthy human subjects.
Frye RF; Branch RA
Br J Clin Pharmacol; 2002 Feb; 53(2):155-62. PubMed ID: 11851639
[TBL] [Abstract][Full Text] [Related]
9. The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes.
Yao HT; Chang YW; Lan SJ; Chen CT; Hsu JT; Yeh TK
Life Sci; 2006 Nov; 79(26):2432-40. PubMed ID: 16978661
[TBL] [Abstract][Full Text] [Related]
10. Clinically significant cytochrome P-450 drug interactions--a comment.
Ford NF; Sonnichsen DS
Pharmacotherapy; 1998; 18(4):890-1; discussion 892-3. PubMed ID: 9692671
[No Abstract] [Full Text] [Related]
11. CYP-mediated clozapine interactions: how predictable are they?
Chetty M; Murray M
Curr Drug Metab; 2007 May; 8(4):307-13. PubMed ID: 17504220
[TBL] [Abstract][Full Text] [Related]
12. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.
Wen X; Wang JS; Backman JT; Kivistö KT; Neuvonen PJ
Drug Metab Dispos; 2001 Nov; 29(11):1359-61. PubMed ID: 11602509
[TBL] [Abstract][Full Text] [Related]
13. Azide inhibits human cytochrome P -4502E1, 1A2, and 3A4.
Salmela KS; Tsyrlov IB; Lieber CS
Alcohol Clin Exp Res; 2001 Feb; 25(2):253-60. PubMed ID: 11236840
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory effects of gypenosides on seven human cytochrome P450 enzymes in vitro.
He M; Jiang J; Qiu F; Liu S; Peng P; Gao C; Miao P
Food Chem Toxicol; 2013 Jul; 57():262-5. PubMed ID: 23583485
[TBL] [Abstract][Full Text] [Related]
15. In vitro studies of induction and inhibition of drug oxidation in man.
Boobis AR; Murray S; Seddon CE; Davies DS
Pharmacol Ther; 1987; 33(1):101-8. PubMed ID: 3628467
[No Abstract] [Full Text] [Related]
16. Drug metabolism and variability among patients in drug response.
Wilkinson GR
N Engl J Med; 2005 May; 352(21):2211-21. PubMed ID: 15917386
[No Abstract] [Full Text] [Related]
17. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol.
Swaisland HC; Ranson M; Smith RP; Leadbetter J; Laight A; McKillop D; Wild MJ
Clin Pharmacokinet; 2005; 44(10):1067-81. PubMed ID: 16176119
[TBL] [Abstract][Full Text] [Related]
18. The induction of CYP1A2, CYP2D6 and CYP3A4 by six trade herbal products in cultured primary human hepatocytes.
Hellum BH; Hu Z; Nilsen OG
Basic Clin Pharmacol Toxicol; 2007 Jan; 100(1):23-30. PubMed ID: 17214607
[TBL] [Abstract][Full Text] [Related]
19. Drug and diet interactions: avoiding therapeutic paralysis.
Jefferson JW
J Clin Psychiatry; 1998; 59 Suppl 16():31-9; discussion 40-2. PubMed ID: 9796864
[TBL] [Abstract][Full Text] [Related]
20. Drinking Ethanol Has Few Acute Effects on CYP2C9, CYP2C19, NAT2, and P-Glycoprotein Activities but Somewhat Inhibits CYP1A2, CYP2D6, and Intestinal CYP3A: So What?
Gazzaz M; Kinzig M; Schaeffeler E; Jübner M; Hsin CH; Li X; Taubert M; Trueck C; Iltgen-Breburda J; Kraus D; Queckenberg C; Stoffel M; Schwab M; Sörgel F; Fuhr U
Clin Pharmacol Ther; 2018 Dec; 104(6):1249-1259. PubMed ID: 29633238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]